Title of Invention

4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS

Abstract

The present invention relates to 4-, 5-, 6- or 7-methylene substituted indolyl derivatives of Formula 1, wherein R is aryl or heteroaryl, where said aryl or heteroaryl groups may be substituted one or more times with a substituent selected from hydrogen, halogen, cyano, nitro, C-<sub>1-6</sub>alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxyl, C<sub>1-6</sub>-alkylthio, hydroxy, hydroxy-C<sub>1-6</sub>-alkyl trifluoromethyl, trifluoromethylsulfonyl, C<sub>1-6</sub>-alkylsulfonyl, amino, C<sub>1-6</sub>-alkylamino, di-(C<sub>1-6</sub>-alkyl) amino, acyl, aminocarbonyl and a methylene dioxy group; X is N, C or CH; provided that the dotted line indicates a bond when X is C and no bond when X is N or CH; R <sup>1</sup> is hydrogen, C<sub>1-6</sub>alkyl, C<sub>-2-6</sub>-alkenyl, C<sub>-2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, aryl, aryl-C<sub>1-6</sub>-alkyl, acyl, thioacyl, C<sub>1-6</sub>-alkylsulfonyl, trifluoromethylsulfonyl or arylsulfonyl; and R<sup>2</sup> and R<sup>3</sup> are independently selected from hydrogen, halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-cycloalkyl-C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio, hydroxy, hydroxy-C<sub>1-6</sub>-alkyl trifluoromethyl, trifluoromethylsulfonyl, C<sub>1-6</sub>-alkylsulfonyl, amino, C<sub>1-6</sub>-alkylamino, di-(C<sub>1-6</sub>-alkyl)amino, acyl and aminocarbonyl; The compounds of the invention are selective dopamine D<sub>4</sub> ligands.

Full Text

4-5,6- and 7-lndole derivatives useful for the treatment of CNS disorders Field of the Invention The present invention relates to a novel class of 4-, 5-, 6- and 7-indole derivatives having aftinity for the dopamine D4 receptor. The compounds are useful in the treatment of certain psychiatric and neurologic disorders, in particular psychoses. Background of the Invention. Dopamine D4 receptors belong to the dopamine D2 subfamily of receptors, which is considered to be responsible for the antipsychotic effects of neuroleptics. The side effects of neuroleptic drugs which primarily exert their effect via antagonism of D2 receptors are known to be due to D2 receptor antagonism in the striatal regions of the brain. However, dopamine D4 receptors are primarily located in areas of the brain other than striatum, suggesting that selective antagonists of the dopamine D4 receptor will be devoid of extrapyramidal side effects. This is illustrated by the antipsychotic clozapine which exerts higher affmity for D4 than D2 receptors and is lacking extrapyramidal side effects (Van Tol et al. Nature 1991, 350, 610; Hadley Medicinal Research Reviews 1996, 16, 507-526, and Sanner Exp. Opin. Ther. Patents 1998, S, 383-393). A number of D4 ligands which were postulated to be selective D4 receptor antagonists (L-745,879 and U-101958) have been shown to posses antipsychotic potential (Ivlansbach et al. Psychophaiinacology 1998, 135, 194-200). However, recently it has been reported that these compounds are partial D4 receptor agonists in various in vitro efficacy assays (Gazi et al. Br. J. Pharmnacol 1998,124, 889-896 and Gazi et al. Br, J. Phannacol 1999,128, 613-620). Furthermore, it was shown that clozapine, which is an effective antipsychotic is a silent D4 antagonist (Gazi et ah BK J. Pharmacol 1999,128, 613-620). Consequently, D4 ligands, which are partial D4 receptor agonists or antagonists, may have beneficial effects against psychoses. Dopamine D4 antagonists may also be useful for the treatment of cognitive deficits (Jentsch at al Psychophannacology 1999, 142, 78-84). It has also been suggested that selective dopamine D4 antagonists may be useful to reduce dyskinesia occurring as a result of the treatment of Parkinson's disease with L-dopa (Tahar et al. Eur. J. PhawiacoL 2000, 399, 1S3-186). Furthermore, evidence for a genetic association between the "primarily inattentive" subtype of attention deficit hyperactivity disorder and a tandem duplication polymorphism in the gene encoding the dopamine D4 receptor has been published (McCracken et al. Mol. Psychiat. 2000, 5, 531-536). This clearly indicates a link between the dopamine D4 receptor and attention deficit hyperactivity disorder and ligands affecting this receptor may be useful for the treatment of this particular disorder Accordingly, dopamirre D4 receptor ligands are potential drugs for the treatment of psychoses, the positive symptoms of schizophrenia, cognitive deficits, attention deficit hyperactivity disorder (ADHD) and dyskinesia resulting from treatment of Parkinson's disease with L-Dopa. In particular, the compounds of the invention are considered usefiil in the treatment of positive symptoms of schizophrenia without inducing extrapyramidal side effects. A number of dopamine D4 ligands which can be described by the general formula wherein Het is 3-pyrrolo[2,3-b]pyridinyl, 2-benzimidazolyl, 3-indazolyl, 2-indoIyl, 3-indolyl, 3-ben2ofuranyl, imidazo[l,2-a]pyridinyl, 3-furo[2,3-b]pyridinyl and 3-benzofiiranyl and Ar is optionally substituted phenyl or heteroaryl, have been described in WO 94/20459, wo 94/20497, WO 94/22839, WO 94/21630, WO 94/24105, WO 99/09025, WO 95/29911, WO 96/25414, US 5.700.802 and J. Med. Chein. 1996, 39(19), 1941-2. wherein Ar is optionally substituted phenyl or thienyl, n is 2-4 and Ind is optionally substituted 4-indolyL The compounds are said to inhibit binding of dopamin agonists and -antagonists to striatal receptors and to have sedative, tranquilizing, antidepressivc neuroleptic, analgetic and antihypertensive effect. The application does not present any biological test results. wherein Ar is 2-inethoxyphenyI or 1-napthyl, n is 2-4 and R is various heterocyclic rings, e.g. 5-oxindole. The compounds are said to have neuroleptic activity, and data showing the ability of the compounds to bind to dopamine D2 receptors are presented in the application. EP patent No. 0 281 309 describes certain piperazinyl-heterocyclic compounds of the formula wherein A together with the phenyl to which it is attached form quinolyl, 2-hydroxyquinolyl, benzothiazolyl, 2-annnoben20thia2;olyl, benzisothiazolyl, indazolyl, 3- hydroxyindazolyl, indolyl, etc., and Ar is substituted naphthyl, quinolyl, isoquinolyl, indolyl, etc. Notably n is 1 or 2. The comounds are said to be useful for the treatment of psychoses and the mechanism primarily via modulation of the dopamine D2-receptor, the serotonine the alfa-adrenergic receptor (7. Me± Chem. 1996, 39, pp.143-148). 5-[[4-(4-fluorophenyl)piperazin-l-yl]methyl]-lH-indole 5-[[4-(4-chlorophenyI)piperidiii-l-yl]methyl]-lH-mdole 5-[[4-(2-chlorophenyl)piperazin-l-yI]methyl]-lH-indoIe 5-[[4-(3-chlorophenyl)piperaziii-l-yl]mediyl]-lH-mdoIe 5-[[4-(23-dichlorophenyl)piperazin-l-yl]methyI]-lH-indoIe 5-[[4-(3,4-dichIoroplienyl)piperazin-l-yl]methyI]-lH-mdole 5-[[4-(4-bromophenyl)piperazin-l-yl]methyl]-lH-indole 5-[[4-(4-iodopheiiyl)piperazin-1-yl]methyl]-lH-indole 5-[[4-(4-liydroxyphenyI)piperazin-l-yl]inethyl]-lH'-indole 5-[[4-(2-methoxyphenyl)piperazin-l-yl]inethyl]-lH-mdole 5-[[4-(3-methoxyphenyl)piperazin-l-yl]methyl]-lH-indoIe 5-[[4-(3,4-dimethoxyphenyl)piperazin-l-yl]methyl]-lH-indole 5-[[4-(4-methylphenyl)piperazin-l-yl]methyl-lH-indole 5-[[4-(4-methylpheriyl)piperidin-l-yl]inethyl]-lH-indole 6-[[4-(4-methylphenyl)piperazin-1 -yl)methyl]- lH-indole In another embodiment, the present invention relates to such compounds wherein R is optionally substituted phenyl In another particular embodiment, the invention relates to a compound as above wherein R w is a group of formula In a particular embodiment of the invention, R is optionally substituted indolyl or phenyl substituted by a methylene dioxy group. In a further particular another embodiment, the present mvention relates to such compounds wherein R is optionally substimted 5- or 6-indoIyl. The invention mcludes in particular such compounds wherein X is N and the dotted line is no bond. The compounds according to the invention also include compounds wherein X is C and the dotted line is a bond. The invention also includes compounds wherein X is CH and the dotted line is no bond. In a further embodiment, the invention relates to compounds wherein R is phenyl which is optionally substituted one or more times with substituents selected from halogen, trifluoromethyl, nitro, cyano, C1-6-alkyl, C1-6-alkoxy, hydroxy and a methylene dioxy group. In another embodiment, the invention relates to compoimds wherein R is indolyl which is optionally substituted one or more times with substituents selected from halogen, trifluoromethyl, nitro, cyano, Ci,6-alkyl, Ci-6-alkoxy and hydroxy. The compounds of the invention are partial agonists or antagonist at the dopamine D4 receptors. Accordingly, the compounds of the invention are considered useful in the treatment of psychoses, positive symptoms of schizophrenia, cognitive deficits, ADHD and dyskinesia resulting from treatment of Parkinson's disease with L-Dopa. In particular, the compounds of the invention are considered useful in the treatment of positive symptoms of schizophrenia without inducing extrapyramidal side effects. Thus, in another aspect, the present invention provides a pharmaceutical composition comprising at least one compound of formula I as defined above or a pharmaceutically acceptable acid addition salt thereof in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents. In a further aspect, the present invention provides the use of a compound of fomiula I as defmed above or an acid addition salt thereof for the manufacture of a pharmaceutical preparation for the treatment of the above mentioned disorders. Detailed Description of the Invention The compounds of the general formula I may exist as optical isomers thereof and such optical isomers are also embraced by the invention. The term Ci-^-alkyl refers to a branched or unbranched alkyl group having fi:om one to six carbon atoms inclusive, such as methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl and 2-methyl-1-propyl. Similarly, C2H5-alkenyl and C2-6-alkynyl, respectively, designate such groups having from two to six carbon atoms, includmg one double bond and one triple bond, respectively, such as ethenyl, propenyl, butenyl, ethynyl, propynyl and butynyl. The term Cs-s-cycloalkyl designates a monocyclic or bicyclic carbocycle having three to eight C-atoms, such as cyclopropyl, cyclopentyl, cyclohexyl, Qtc. Halogen means fluoro, chloro, bromo or iodo. As used herein, the term acyl refers to a formyl. C1-6 -alkylcarbonyl, arylcarbonyl, aryl-C1-6-alkylcarbonyl, C3-8-cycloalkylcarbonyl or a C3-8-cycloalkyl-C1-6-alkyl-carbonyl group and the term thioacyl is the corresponding acyl group, in which the carbonyl group is replaced with a thiocarbonyl group. The terms C1-6-allcoxy, C3-8-cycIoalkyl-C1-6-alkyl, C1-6-alkylsulfonyl, C1-6-alkylaraino, C1-6-alkylcarbonyl, and the like, designate such groups in which the alkyl group is C1-6 alkyl and C1-6 all-cyl and the C3-8-cycloalkyl group are as defined above. The terra aryl refers to a carbocyclic aromatic group, such as phenyl or naphthyl. in particular phenyl. wherein A is an optionally substituted, saturated or unsaturated heterocyclic ring which may contain one or two heteroatoms selected from N, O and S. The formula covers for example such bicyclic rings which are mentioned in the list above. The substituents on A may be one or more substituents selected from hydrogen, halogen, cyano, nitro, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-8-cycloalkyl, C3-8-cycloa!kyl-C1-6-alkyl, C1-6 allkoxy, C1-6-aIkylthio, hydroxy, hydroxy-C1-6-alkyl trifluoromethyl, trifluoromethylsulfonyl, C1-6-alkylsulfonyl, amino, C1-6-alkylamino, di-(C1-6-alkyl)amino, acyl and aminocarbonyl. The acid addition salts of the compounds of the invention are pharmaceutically acceptable salts formed with non-toxic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, succinic, oxahc, bis-methylenesalicylic, methanesuifonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, mahc, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. The pharmaceutical compositions of this invention, or those which are manufactured in accordance with this invention, may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection. For preparing such compositions, methods well known in the art may be used, and any pharmaceutically acceptable carriers, diluents, excipients or other additives normally used in the art may be used. Conveniently, the compounds of the invention are administered in linit dosage form containing said compounds in an amount ofabout 0.01 to 100 mg. The total daily dose is usually m the range of about 0.05 - 500 mg, and most preferbly about 0.1 to 50 mg of the active compound of the invention. The compounds of the invention may be prepared as follows: wherein R, R1 R2, R3, X and the dotted line are as previously defined. c) Reducing the double bond in the tetrahydropyridinyl ring in derivatives of formula V: The reduction according to method a) is preferably carried out in an inert organic solvent such as diethyl ether or tetrahydrofuran in the presence of alane or lithium aluminium hydride from 0 °C to reflux temperature. Starting compounds of formula (II) are generally prepared by coupling of an amine of formula (HI) with an appropriately substituted indolyl carboxylic acid by standard methods via the carboxylic acid chloride, activated esters or by the use of carboxylic acids in combination with a coupling reagent such as e.g. dicyclohexyl carbodiimide. Amines of formula (III) are either commercially available or can be prepared by standard literature methods (see e.g. J. Med. Chem. 1991, 34, 2014-2023; J.Med. Chem. 1998, 41, 658-667). 3-(piperidin-4-yl)-l//-indoles and (3,6-dihydro-2/7-pyridin-4-yl}-l//-indoles have been described m the Uterature (see EP-Al-465398). The reduction according to method b) is carried out by a standard one-pot procedure, e.g. using a reductive amination of amines of formula (IQ) and aldehydes of formula (IV). Starting compounds of formula (IV) and appropriately substituted indolyl carboxylic acids are either commercially available or can be synthesised by methods described in the literature or in standard works such as Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Georg-Thieme-Verlag, Stuttgart; Organic Reactions, John Wiley & Sons, Inc. New York, namely under reaction conditions such as those which are known and suitable for such reactions. The reduction of the double bond according to method c) is generally performed by catalytic hydrogenation at low pressure ( Experimental Section Melting points were determined on a Biichi SMP-20 apparatus and are uncorrected. Analytical LC-MS data were obtained on a PE Sciex API 150EX instrument equipped with lonSpray source and Shimadzu LC-8A/SLC-10A LC system. The LC conditions (CIS column 4.6 x 30 mm with a particle size of 3.5 µm) were linear gradient elution with water/acetonitrile/trifluoroacetic acid (90:10:0.05) to water/acetonitrile/trifluoroacetic acid (10:90:0.03) in 4 min at 2 mL/min. Purity was determined by integration of the UV trace (254 nm). The retention times, Rt, are expressed in minutes. Mass spectra were obtained by an alternating scan method to give molecular weight Examples la, 5'[[4-(4'ChlorQphenyl)piperazin~l'yl]methyi]'lH-indole, Indole-5-carboxylic acid (1,62 g) was dissolved in dry THF (20 mL). Carbonyl diimidazole (1.62 g) was added, and the mixture was stirred at room temperature for 60 min, 4-(4" chlorophenyl)piperazine (1.9 g) dissolved in dry THF (20 mL) was added in one portion and the mixture was stirred at room temperature for 5 h. The solvent was removed in vacuo, and the remaining solid was dissolved in EtOAc (400 mL), washed with 10% aqueous sodium carbonate (100 mL), 1 M acetic acid (100 ml), brine (100 mL), dried (MgS04) and evaporated in vacuo to give a white solid (2.3 g). The solid was dissolved in dry THF (40 mL) and subsequently added dropwise to a cooled solution of alane in THF (prepared by the careful addition of 0.6 g cone, sulfuric acid to a suspension of 0.47 g lithium aluminium hydride in 20 mL dry THF). The mixture-was stirred at 15 °C for 2 h, quenched by the -addition of water (1 mL), cone. NaOH {½ mL) and water (2 mL). The white precipitate was removed by filtration and the THF evaporated in vacuo to give the product as a white solid. Recrystallisation from MeCN gave 1.8 g 5-[[4-(4-chlorophenyl)pipera2in-l-yl]methyl]indole as white crystals. Mp 175-176°C; Analysis calcd. (C19H20CIN3): C:70.04, H: 6.19, N: 12.90; found. C: 69.94, H: 6.25, N: 12.90. 1H NMR (DMSO-d6): 3.10 (m, 4H); 3.40 (m, 4H); 3.50 (s, 2H); 6.40 (s, 1H); 6.90 (d, 2H); 7.10 (d, 1H); 7.21 (d, 2H); 7.30 (m, 2H); 7.45 (s,1IH). The following compound was prepared in a similar manner: lb, 5'[f4-(5-indolyl)piperazin'I--yl]methyl]-lH'indole^ 1H NMR (DMSO-d6): 2.55 (m, 4H); 3.00 (m, 4H); 3.50 (s, 2H); 6.25 (s,1IH), 6.45 (s, 1H); 6.85 (m, 1H); 6.95 (m, 1H); 7.05 (m, 1H); 7.20 (m, 3H); 7.30 (m, 2H); 7.45 (s, 1H); 10.80 (s, 1H); 11.00 (s,lH). 1 c, 5-[f4-(4-methoxyphmyl)piperazin'l-yl]methyl]-lH4ndole ^HNMR(DMS0-d6): 2.60 (m, 4H); 3.10 (m, 4H); 3.60 (s, 2H); 3.70 (s, 3H); 6.40 (s, 1H); 6.80 (d, 2H); 6.90 (m, 2H), 6.95 (d, 1H); 7.30 (m, 2H); 7.45 (m,1IH), 11.00 (s,1IH). Id, 5'ff4-pkenylpiperazin-I'yl]methylJ-lH-vidole 1H NMR (DMSO-d6): 2.60 (m, 4H); 3.10 (m, 4H); 3.60 (s, 2H); 635 (s, 1H); 6.75 (m, IE); 6.90 (m, 2H); 7.05 (m, 1H); 7.15 (m, 2H); 7.35 (m, 2H); 7.45 (s, 1H); 11.00 (s,1IH). I e, 5-f4-(4-ChlorophenvI)-3,6-dihvdro'2H-pyndm-J-vlinethylJ-IH-indole 'H NMR (DMSO-d^): 2.45 (m, 2H); 2.65 (m, 2H), 3.05 (m, 2H); 3.60 (s, 2H); 6.20 (m, Iff), 6.40 (s, 1H); 7.10 (m, 1H); 7.30-7.40 (m, 4H); 7.40-7.50 (m, 3H); U.OO (s,1IH). 1H NMR (DMSO-d6): 2.55 (m, 4H); 3.10 (m, 4H); 3.60 (s, 2H); 6.40 (s, 1H); 6.90 (d, 2H); 7.10 (d, 1H); 7.20 (d, 2H); 7.30 (m, 1H); 7.40 (m, 1H), 7.50 (s, 1H), 11.00 (s, IH). The following compounds may also be prepared according to the invention: 5'[[4-(4-fliiorophenyl)piperazin'l-yl]methyl]-lH-indole 5-[[4-(4-chlorophenyl)piperidm-l-yl]methyl]-lH'-indoIe 5-[[4-(2-chloropheuyl)piperazm-1 -yl]methyl]- lH-indole 5-[[4-(3-chlorophenyl)pipera2in-1 -yl]methyl]-lH-indole 5-[[4-(2,3-dichlorophenyl)piperazin-l-yl]methyI]-lH-indole 5-[[4-(3,4-dichIorophenyI)piperazin-l-yl]methyl]-lH-indole 5-[[4-(4-bromophenyl)pipera2in-l-yl]methyIj-lH-indoie 5-[[4-(4-iodophenyl)piperazin-1 -yl]methyl]-lH-indole 5-[[4-(4-hydroxyphenyl)pipera2in-1 -yl]methyl]- lH-indoIe 5-[[4-(2-methoxyphenyl)piperazin-1 -yljmethyl]- lH-indole 5-[[4-(3-methoxyphenyl)piperazin-l-yl]methyl]-lH-indole 5-[[4-(3,4-dimethoxyphenyl)piperazin-l-yI]methyl]-lH-indoIe 5-[[4-(4-methylphenyl)pipera2in-l-yl]methyI]-lH-indole 5-[[4-(4-methylphenyl)piperidin-l-yl]methyl]-lH'-indole 6-[[4-(4-methylphenyl)piperazin-l-yl]methyl]-l-/i/'-indole 6-[[4-(4-inethylphenyl)piperidin-l-yl]methyl]-lH-indole 5-[[4-(4-Chlorophenyl)pipera2in-1 -yljmethyl]-1 -methyH/f-indole 6-[[4-(4-Chlorophenyl)piperazin-l-yl]methyl]-l-methyl-lH-indole 5-[[(4-Benzo[l,3]dioxol-5-yl-)piperazin-l-yl]methyl]-llH-indole Pharmacological Testing The compoimds of the invention were tested in well-recognised and reliable tests. The tests were as follows: Inhibition of binding of [^H]YiVI-09151-2 to D4.2 receptors By this method, the inhibition by drugs of the binding of [3H]YM-09151-2 (0.06 nM) to membranes of human cloned dopamine D4.2 receptors expressed in CHO-cells is determined in vitro. The method is modified from NEN Life Science Products, Inc., teclinical data certificate PC2533-10/96. Inhibition of the binding of [3H]Spiperone to D2 receptors The compounds were tested with respect to affinity for the dopamine D2 receptor by determining their ability to inhibit the binding of [3H]Spiperone to D2 receptors by the method of Hyttel et al. J. Neiirochem, 1985, 44, 1615. In table 1 below, the test results are shown: Thus, the compounds of the invention are considered useful in the treatment of psychoses positive and negative symptoms of schizophrenia, cognitive disorders, ADHD and dyskinesia resulting from treatment of Parkinson's disease with L-Dopa. In particular, the compounds of the invention are considered useful in the treatment of positive and negative symptoms of schizophrenia without inducing extrapyramidal side effects. Formulation Examples The pharmaceutical formulations of the invention may be prepared by conventional methods in the art. For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tabletting machine. Examples of adjuvants or diluents comprise: com starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients. Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to the desired volume, sterilising the solution and filling it in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc. Typical examples of recipes for the formulation of the invention are as follows: 1) Tablets containing 5.0 mg of a compound of the mvention calculated as the free base: Compound 1 a or lb 5.0 mg Lactose 60 mg Maize starch 30 mg Hydroxypropylcellulose 2.4 mg Microcrystalline cellulose 19,2 mg Croscarmellose Sodium Type A 2.4 mg Magnesium stearate 0.84 mg 2) Tablets containing 0.5 mg of a compound of the invention calculated as the free base: Compound la or lb 0.5 rag Lactose 46.9 mg Maize starch 23.5 mg Povidone 1.8 mg Microcrystalline cellulose 14.4 rag Croscannellose Sodium Type A 1.8 mg Magnesium stearate 0,63 mg 3) Syrup containing per millilitre: Compound la or lb 25 mg Sorbitol 500 mg Hydroxypropylcellulose 15 mg Glycerol 50 mg Methyl-paraben 1 mg Propyl-paraben 0.1 mg Ethanol 0.005 ml Flavour 0.05 mg Saccharin sodium 0.5 mg Water ad 1 ml 4) Solution for injection containing per millilitre: Compound la or lb 0.5 mg Sorbitol 5.1 mg Acetic Acid 0.05 mg Saccharin sodium 0.5 mg Water ad 1 ml wherein R is aryl or heteroaryl, where said aryl or heteroaryl group may be substituted one or more times with a substituent selected from halogen, cyano, nitro, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl, C1-6-alkoxy, Ci^-alkylthio, hydroxy, hydroxy-C1-6-alkyl, trifluoromethyl, trifluoromethylsulfonyl, Ci-6-alkylsulfonyl, amino, C1-6-alkylamino, di-(C1-6-allcyl)amino, acyl, aminocarbonyl and a methylene dioxy group; X is N, C or CH; provided that the dotted line indicates a bond when X is C and no bond when X is N or CH; R1 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl, aryl, aryl-Ci^-alkyl,'acyl, thioacyl, C1-6-alkylsulfonyl, trifluoromethylsulfonyl or arylsulfonyl; and R^ and R3 are independently selected from hydrogen, halogen, cyano, nitro, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl, C1-6-alkoxy, C1-6-alkylthio, hydroxy, hydroxy-C1-6-alkyl trifluoromethyl, trifluoromethylsulfonyl, C1-6-alkylsulfonyl, amino, C1-6-alkylamino, di-(C1-6-alkyl)amino, acyl and aminocarbonyl; or a pharmaceutically acceptable salt thereof 2. A compound according to claim 1, wherein the indole is attached to the group wherein A is an optionally substituted, saturated or unsaturated heterocyclic ring which may contain one or two heteroatoms selected from N, 0 and S. 5. The compound according to claim 4 wherein R is optionally substitute indolyl or phenyl substituted by a methylene dioxy group. 6. The compound according to claims 1-2, wherein X is N. 7. The compound according to claims 1-2, wherein X is C and the dotted line is a bond. 8. The compound according to claims 1-2, wherein X is CH and the dotted line is no bond. 9. The compound according to claim 3, wherein the phenyl group R is optionally substituted one or more times with substituents selected from halogen, trifluoromethyl, nitro, cyano, C1-6-alkyl, C1-6 -alkoxy, hydroxy and a methylene dioxy group. 10. The compound according to claim 4, wherein the group R is optionally substituted one or more times with substituents selected from halogen, trifluoromethyl, nitro, cyano, C1-6-alkyl, C1-6-alkoxy and hydroxy. 11. The compound according to claim 1, which is 5-[[4-(4-chlorophenyl)pipera2in-l-yl]methyl]-lH-indole 5'[[4-(5-indolyl)piperazin-l-yl]methyl]-lH-indole, 5-[[4-(4-methoxyphenyl)piperazin-l-yl]methyl]-lH-indole 5-[[4-phenylpiperazin-l-yl]methyl]-li?-indole 5-[4-(4-Chlorophenyl)-3,6-dihydro-2i7-pyridin-1 -ylmethyl]- lH-indole 6-[[4-(4-chlorophenyl)pipera2in-l -yljmethylj- IH-indole 6"[[4-(4-methoxyphenyl)pipera2in-l-yl]methyl]-lH-indole 12. A pharmaceutical composition characterised in that it comprises a compoimd of any of r claims 1 to 11 in a therapeutically effective amount together with one or more phamiaceuti-cally acceptable carriers or diluents, 13. Use of a compound of any of claims 1 to 11 for the manufacture of a medicanjent useful in the treatment of psychoses, positive symptoms of schizophrenia, cognitive deficits, ADHD and dyskinesias resulting from treatment of Parkinson's disease with L-Dopa. 14. A method of treating the positive symptoms of schizophrenia, other psychoses, cognitive disorders comprising administration of a therapeutically acceptable amount of a compoimd according to any of claims 1 to 11. 15. A "4-,5-,6—or 7-methylene substituted indolyl derivative of formula I, substantially as hereinabove described and exemplified.

Documents:

401-chenp-2003-abstract.pdf

401-chenp-2003-claims filed.pdf

401-chenp-2003-claims granted.pdf

401-chenp-2003-correspondnece-others.pdf

401-chenp-2003-correspondnece-po.pdf

401-chenp-2003-description(complete)filed.pdf

401-chenp-2003-description(complete)granted.pdf

401-chenp-2003-form 1.pdf

401-chenp-2003-form 18.pdf

401-chenp-2003-form 26.pdf

401-chenp-2003-form 3.pdf

401-chenp-2003-form 5.pdf

401-chenp-2003-other documents.pdf

401-chenp-2003-pct.pdf